What is Immutep?
Immutep, established in 2001 and headquartered in Sydney, New South Wales, is a prominent biotechnology firm specializing in the development of novel cancer immunotherapies. The company's core focus lies in harnessing the body's immune system to combat various forms of cancer. Their strategic approach to drug development aims to create innovative therapeutic solutions for unmet medical needs within oncology.
How much funding has Immutep raised?
Immutep has raised a total of $140M across 3 funding rounds:
Share Placement
$7M
Other Financing Round
$80M
Other Financing Round
$53M
Share Placement (2019): $7M, investors not publicly disclosed
Other Financing Round (2023): $80M, investors not publicly disclosed
Other Financing Round (2024): $53M, investors not publicly disclosed
What's next for Immutep?
With the recent major strategic investment, Immutep is poised for accelerated growth and the advancement of its therapeutic pipeline. This enterprise-level funding is expected to fuel further research and development, potentially leading to expanded clinical trials and the commercialization of its promising immunotherapies. The company's strategic financial backing signals confidence from investors in its long-term vision and its potential to make a significant impact in the field of cancer treatment.
See full Immutep company page
